ENDRA Life Sciences reports preliminary Q1 2023 net loss of $2.8M; no revenue

ENDRA Life Sciences Inc.

Expects no revenue for Q1 2023, consistent with Q1 2022.
Net loss approximately $2.8M, improving from $2.9M loss in prior year.
Cash and cash equivalents $2.4M; total assets $6.7M; working capital $4.3M.
Filed S-1/A for underwritten public offering of common stock and warrants.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ENDRA Life Sciences Inc. reported the quarter ended March 31, 2023 results: revenue no revenue, net income net loss of approximately $2.8 million.

Period: the quarter ended March 31, 2023
Revenue: no revenue
Net income: net loss of approximately $2.8 million
Result: preliminary results

Exact text from the filing

We expect no revenue for the quarter ended March 31, 2023 and did not have revenue for the quarter ended March 31, 2022. We expect to record a net loss of approximately $2.8 million for the quarter ended March 31, 2023, compared to a net loss of approximately $2.9 million for the quarter ended March 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

ENDRA Life Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-004872

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.